Morningstar has valued the stock at $207 (up from $200 immediately prior to release of full year results).
They attribute approximately $57 of this $207 to the success of CSL112 (i.e. if it failed, they would removed $57 from share price valuation). They have a 50% chance of success on the CSL112 drug so I imagine if it became successful, Morningstar would add $57 to valuation.
A while ago someone posted that Goldman Sachs have a price target of $225. Does anyone have updated reports or price targets from Goldman Sachs or other brokers?
Morningstar has valued the stock at $207 (up from $200...
-
- There are more pages in this discussion • 115 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$288.79 |
Change
-0.140(0.05%) |
Mkt cap ! $139.8B | |||
| Open | High | Low | Value | Volume |
| $289.90 | $290.00 | $287.43 | $81.59M | 282.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1859 | $288.71 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $288.79 | 8 | 1 |
View Market Depth
| Last trade - 16.10pm 07/10/2024 (20 minute delay) ? |
| CSL (ASX) Chart |